CYRX · CryoPort, Inc.

Current Thesis

Cryoport is the picks-and-shovels cold-chain layer for cell & gene therapy (CGT): cryogenic logistics, storage, and packaging that taxes the whole CGT pipeline rather than betting on which therapy wins. The 2026 re-rate ran on three legs FDA loosening CGT manufacturing requirements (Jan 2026, dropped the 3-round PPQ mandate), a biotech funding recovery refilling the trial pipeline, and accelerating commercial CGT revenue (+26% YoY at the 2026-05-04 Q1 print). Craig-Hallum (Matthew Hewitt) pushed the PT to a street-high $20 from $15 on 2026-06-03; the stock spiked to a 52-week high of $16.73, then faded ~6% to ~$15.70 by 2026-06-06. The problem is timing: the 8-analyst consensus PT now sits at $15.31 essentially AT spot so the "ahead of sell-side" edge that defined this name in May is gone. No company-specific binary lands until the Q2 print (~early August). This is a maturing move; a fresh entry here is a probe, with materially better risk/reward on a retest of the $13–14 breakout shelf.

Bull Case

• Commercial CGT revenue +26% YoY to $9.1M (Q1 2026, 2026-05-04) the high-margin recurring leg is accelerating, not the lumpy clinical leg.
• FY2026 revenue guidance RAISED to $192–196M at the Q1 print (8-K / TradingView, 2026-05-04) a raise on improved visibility, not a maintain.
• Q1 revenue $47.8M, +16% YoY, beat $45.76M consensus; Life Sciences Services +18% YoY to $26.9M (2026-05-04).
• Path to profitability narrowing: Q1 adjusted EBITDA -$0.6M, gross margin 45.8%; management guides positive adjusted EBITDA in 2H 2026 on organic growth + completed facility investments (Q1 call, 2026-05-04).
• New product cycle: MVE Fusion 800 Series, a self-sustaining cryogenic freezer that removes the need for continuous liquid-nitrogen supply, won the ISBER Outstanding New Product Award TAM extension into hospitals, clinics, biorepositories, and blood/tissue banks.
• Regulatory + reimbursement tailwind: FDA CGT manufacturing-flexibility (Jan 2026) plus the CMS Cell & Gene Therapy Access Model widen the trial-to-commercial path → more cold-chain volume downstream.
• Street rating Strong Buy, 8 analysts, 0 holds/sells (as of 2026-05-25); Craig-Hallum street-high $20 PT (2026-06-03).

Bear Case

• The re-rate is largely spent: stock ~3x off the $6.16 52-week low, ~$783M market cap, and spot ~$15.70 sits ABOVE the $15.31 consensus PT only Craig-Hallum's $20 prints above price.
• The 2026-06-03 pop was a sentiment move on a single note and faded ~6% within two sessions to $15.70 (2026-06-06) the late-entry chase signature.
• Still unprofitable: Q1 operating loss widened to $9.6M (from $7.2M YoY); EPS -$0.23 missed by a penny (2026-05-04). Positive adjusted EBITDA is a 2H guide, not a printed result.
• Premium for a logistics/services business: P/S ~4.5x. The reported low PE on data feeds is an artifact of operating losses don't frame valuation on it.
• Catalyst vacuum for ~2 months: Q1 is done, Q2 lands ~early August → the tape trades on sentiment and XBI risk appetite, not events.
• Demand is a derivative of CGT-developer funding: program attrition (Galapagos and Takeda dropped cell-therapy programs in late 2025) directly erodes the installed base.

Setup & Price Structure

• Spot ~$15.70 (2026-06-06), down from the 2026-06-03 Craig-Hallum-pop close (~$16.50) and the $16.73 intraday 52-week high sitting just off the high, top of the range.
• 52-week range $6.16 $16.73; clean, persistent uptrend off the lows, but now extended into resistance with no overhead supply and no cushion below.
• Consensus PT $15.31 (8 analysts) ≈ spot no headroom on the average target, the edge now rests entirely on Craig-Hallum's outlier.
• Breakout pivot / 20-week EMA support zone ~$13–14 is the reference for a higher-low re-entry; a weekly close beneath it breaks the structure.
• Momentum cooled from the overbought pop as price faded ~6% over two sessions digesting, not thrusting. No fresh impulse leg to chase here.
• Theme status: MATURING. The narrative re-rated and sell-side has converged on it; this is not a fresh ACCELERATING breakout with the Street still behind it.

Catalyst Calendar (next 30 days)

• No company-specific binary inside the window. Q2 2026 print ~early August (est.) sits outside 30 days EARNINGS BLACKOUT within 3 trading days of the confirmed date.
• MVE Fusion 800 commercial ramp / order datapoints unscheduled; watch press releases for early traction.
• Biotech/healthcare conference circuit + XBI risk sentiment the macro tell for CGT-developer funding; no dated single event.
• No FDA/PDUFA or analyst-cluster event scheduled in the window.

What Would Change Our Mind

• Bull confirmation (better entry): a pullback to $13–14 that holds as a higher low, plus re-acceleration of commercial CGT revenue at Q2 → a maturing-theme dip worth sizing into rather than the analyst-pop high.
• Invalidation: weekly close below ~$13 (loses the breakout pivot / 20-week EMA); FY2026 guide cut below the $192M floor at the Q2 print; or commercial CGT growth decelerating below +15% YoY (was +26% in Q1).
• Theme flip: CGT-funding sentiment rolling over (XBI breakdown) or a cluster of customer-program cancellations → demote to SATURATED/DEAD and stand aside.

Correlation Notes

• Primary driver is XBI / small-cap biotech risk sentiment Cryoport demand is downstream of CGT-developer funding, not therapy approvals, so it tracks the biotech funding cycle more than any single drug readout.
• Correlated to large-cap CGT developers and CDMOs whose pipelines feed the cold chain; peer-program cancellations (Galapagos, Takeda, 2025) are direct read-throughs to the installed base.
• Idiosyncratic to FDA/CMS CGT policy; rate-sensitive only via small-cap biotech risk appetite. No meaningful AI/semis correlation this is a healthcare-logistics name, not a tech-momentum proxy.